The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus

A meta-analysis

Tusar K. Desai, Kumar Krishnan, Niharika Samala, Jashanpreet Singh, John Cluley, Subaiah Perla, Colin Howden

Research output: Contribution to journalArticle

282 Citations (Scopus)

Abstract

Introduction: The risk of oesophageal adenocarcinoma (OAC) in non-dysplastic Barrett's oesophagus (BO) may have been overestimated. The objective was to estimate the incidence of OAC in patients with BO without dysplasia. Methods: The authors searched MEDLINE and EMBASE from 1966 to 2011 and performed a bibliographic review of previous publications, excluding abstracts, non-peerreviewed publications and those not published in English, for prospective or retrospective studies of the incidence of OAC in patients with BO. They excluded patients with any degree of dysplasia at baseline and those without documented intestinal metaplasia. Studies were independently reviewed by two individuals. 57 of 3450 studies were included. The authors extracted information on number of patients with BO, length of follow-up, incident cases of OAC, mean age of patients, country of origin, whether prospective or retrospective, mean length of BO segments and mortality from causes other than OAC. Study quality was assessed by the Ottawa Newcastle criteria. Results: The 57 included studies comprised 11 434 patients and 58 547 patient-years of follow-up. The pooled annual incidence of OAC was 0.33% (95% CI 0.28% to 0.38%). Among 16 studies that provided appropriate information on mortality, there were 56 incident cases of OAC but 684 deaths from apparently unrelated causes. Among 16 studies that provided information on patients with short-segment BO, the annual incidence of OAC was only 0.19%. Conclusions: The incidence of OAC in non-dysplastic BO is around 1 per 300 patients per year. The incidence of OAC in short-segment BO is under 1 per 500 patients per year.

Original languageEnglish (US)
Pages (from-to)970-976
Number of pages7
JournalGut
Volume61
Issue number7
DOIs
StatePublished - Jul 1 2012
Externally publishedYes

Fingerprint

Barrett Esophagus
Meta-Analysis
Adenocarcinoma
Incidence
Mortality
Metaplasia
MEDLINE
Publications
Retrospective Studies
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus : A meta-analysis. / Desai, Tusar K.; Krishnan, Kumar; Samala, Niharika; Singh, Jashanpreet; Cluley, John; Perla, Subaiah; Howden, Colin.

In: Gut, Vol. 61, No. 7, 01.07.2012, p. 970-976.

Research output: Contribution to journalArticle

Desai, TK, Krishnan, K, Samala, N, Singh, J, Cluley, J, Perla, S & Howden, C 2012, 'The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: A meta-analysis', Gut, vol. 61, no. 7, pp. 970-976. https://doi.org/10.1136/gutjnl-2011-300730
Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: A meta-analysis. Gut. 2012 Jul 1;61(7):970-976. https://doi.org/10.1136/gutjnl-2011-300730
Desai, Tusar K. ; Krishnan, Kumar ; Samala, Niharika ; Singh, Jashanpreet ; Cluley, John ; Perla, Subaiah ; Howden, Colin. / The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus : A meta-analysis. In: Gut. 2012 ; Vol. 61, No. 7. pp. 970-976.
@article{4c89115e074342818afd4b2fa7b803bd,
title = "The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: A meta-analysis",
abstract = "Introduction: The risk of oesophageal adenocarcinoma (OAC) in non-dysplastic Barrett's oesophagus (BO) may have been overestimated. The objective was to estimate the incidence of OAC in patients with BO without dysplasia. Methods: The authors searched MEDLINE and EMBASE from 1966 to 2011 and performed a bibliographic review of previous publications, excluding abstracts, non-peerreviewed publications and those not published in English, for prospective or retrospective studies of the incidence of OAC in patients with BO. They excluded patients with any degree of dysplasia at baseline and those without documented intestinal metaplasia. Studies were independently reviewed by two individuals. 57 of 3450 studies were included. The authors extracted information on number of patients with BO, length of follow-up, incident cases of OAC, mean age of patients, country of origin, whether prospective or retrospective, mean length of BO segments and mortality from causes other than OAC. Study quality was assessed by the Ottawa Newcastle criteria. Results: The 57 included studies comprised 11 434 patients and 58 547 patient-years of follow-up. The pooled annual incidence of OAC was 0.33{\%} (95{\%} CI 0.28{\%} to 0.38{\%}). Among 16 studies that provided appropriate information on mortality, there were 56 incident cases of OAC but 684 deaths from apparently unrelated causes. Among 16 studies that provided information on patients with short-segment BO, the annual incidence of OAC was only 0.19{\%}. Conclusions: The incidence of OAC in non-dysplastic BO is around 1 per 300 patients per year. The incidence of OAC in short-segment BO is under 1 per 500 patients per year.",
author = "Desai, {Tusar K.} and Kumar Krishnan and Niharika Samala and Jashanpreet Singh and John Cluley and Subaiah Perla and Colin Howden",
year = "2012",
month = "7",
day = "1",
doi = "10.1136/gutjnl-2011-300730",
language = "English (US)",
volume = "61",
pages = "970--976",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "7",

}

TY - JOUR

T1 - The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus

T2 - A meta-analysis

AU - Desai, Tusar K.

AU - Krishnan, Kumar

AU - Samala, Niharika

AU - Singh, Jashanpreet

AU - Cluley, John

AU - Perla, Subaiah

AU - Howden, Colin

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Introduction: The risk of oesophageal adenocarcinoma (OAC) in non-dysplastic Barrett's oesophagus (BO) may have been overestimated. The objective was to estimate the incidence of OAC in patients with BO without dysplasia. Methods: The authors searched MEDLINE and EMBASE from 1966 to 2011 and performed a bibliographic review of previous publications, excluding abstracts, non-peerreviewed publications and those not published in English, for prospective or retrospective studies of the incidence of OAC in patients with BO. They excluded patients with any degree of dysplasia at baseline and those without documented intestinal metaplasia. Studies were independently reviewed by two individuals. 57 of 3450 studies were included. The authors extracted information on number of patients with BO, length of follow-up, incident cases of OAC, mean age of patients, country of origin, whether prospective or retrospective, mean length of BO segments and mortality from causes other than OAC. Study quality was assessed by the Ottawa Newcastle criteria. Results: The 57 included studies comprised 11 434 patients and 58 547 patient-years of follow-up. The pooled annual incidence of OAC was 0.33% (95% CI 0.28% to 0.38%). Among 16 studies that provided appropriate information on mortality, there were 56 incident cases of OAC but 684 deaths from apparently unrelated causes. Among 16 studies that provided information on patients with short-segment BO, the annual incidence of OAC was only 0.19%. Conclusions: The incidence of OAC in non-dysplastic BO is around 1 per 300 patients per year. The incidence of OAC in short-segment BO is under 1 per 500 patients per year.

AB - Introduction: The risk of oesophageal adenocarcinoma (OAC) in non-dysplastic Barrett's oesophagus (BO) may have been overestimated. The objective was to estimate the incidence of OAC in patients with BO without dysplasia. Methods: The authors searched MEDLINE and EMBASE from 1966 to 2011 and performed a bibliographic review of previous publications, excluding abstracts, non-peerreviewed publications and those not published in English, for prospective or retrospective studies of the incidence of OAC in patients with BO. They excluded patients with any degree of dysplasia at baseline and those without documented intestinal metaplasia. Studies were independently reviewed by two individuals. 57 of 3450 studies were included. The authors extracted information on number of patients with BO, length of follow-up, incident cases of OAC, mean age of patients, country of origin, whether prospective or retrospective, mean length of BO segments and mortality from causes other than OAC. Study quality was assessed by the Ottawa Newcastle criteria. Results: The 57 included studies comprised 11 434 patients and 58 547 patient-years of follow-up. The pooled annual incidence of OAC was 0.33% (95% CI 0.28% to 0.38%). Among 16 studies that provided appropriate information on mortality, there were 56 incident cases of OAC but 684 deaths from apparently unrelated causes. Among 16 studies that provided information on patients with short-segment BO, the annual incidence of OAC was only 0.19%. Conclusions: The incidence of OAC in non-dysplastic BO is around 1 per 300 patients per year. The incidence of OAC in short-segment BO is under 1 per 500 patients per year.

UR - http://www.scopus.com/inward/record.url?scp=84861579225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861579225&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2011-300730

DO - 10.1136/gutjnl-2011-300730

M3 - Article

VL - 61

SP - 970

EP - 976

JO - Gut

JF - Gut

SN - 0017-5749

IS - 7

ER -